[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@DaiichiSankyoUS Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1169299794696818688.png) @DaiichiSankyoUS Daiichi Sankyo US

Daiichi Sankyo US posts on X about $8750t, $4568t, $6417t, click the the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1169299794696818688/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1169299794696818688/c:line/m:interactions.svg)

- X Week XXX -XX%
- X Month XXXXX +24%
- X Months XXXXXXX -XX%
- X Year XXXXXXXXX -XX%

### Mentions: X [#](/creator/twitter::1169299794696818688/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1169299794696818688/c:line/m:posts_active.svg)

- X Week X no change
- X Month XX +43%
- X Months XX +76%
- X Year XX +729%

### Followers: XXXXX [#](/creator/twitter::1169299794696818688/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1169299794696818688/c:line/m:followers.svg)

- X Week XXXXX +0.05%
- X Month XXXXX +0.18%
- X Months XXXXX +1.50%
- X Year XXXXX +1.80%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1169299794696818688/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1169299794696818688/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1169299794696818688/influence)
---

**Social category influence**
[countries](/list/countries)  XXXX%

**Social topic influence**
[$8750t](/topic/$8750t) #8, [$4568t](/topic/$4568t) #1, [$6417t](/topic/$6417t) #2, [click the](/topic/click-the) #2546, [breast cancer](/topic/breast-cancer) 6.67%, [directed](/topic/directed) 3.33%, [adc](/topic/adc) 3.33%, [san diego](/topic/san-diego) 3.33%, [japan](/topic/japan) XXXX%

**Top accounts mentioned or mentioned by**
[@astrazenecaus](/creator/undefined) [@nmx_research](/creator/undefined) [@merck](/creator/undefined) [@linhnguyen64143](/creator/undefined) [@oncodaily](/creator/undefined) [@atoppsummit](/creator/undefined) [@myesmo](/creator/undefined) [@ethan_taylor008](/creator/undefined) [@bioworld](/creator/undefined) [@afidrocolombia](/creator/undefined) [@biolabs](/creator/undefined) [@fda](/creator/undefined) [@gracequest](/creator/undefined) [@biopharmadive](/creator/undefined) [@pharmavoice](/creator/undefined) [@asco](/creator/undefined) [@uniteforher](/creator/undefined) [@_idmedica](/creator/undefined) [@meenu721812551](/creator/undefined) [@inside_pm](/creator/undefined)
### Top Social Posts [#](/creator/twitter::1169299794696818688/posts)
---
Top posts by engagements in the last XX hours

"#BREAKINGNEWS: Daiichi Sankyo joins @BioLabs the leading international innovation platform and network of premier shared laboratory spaces as Platinum Sponsor; providing BioLabs with direct access to Daiichi Sankyo scientific leaders and expertise. Click the image for more"  
[X Link](https://x.com/DaiichiSankyoUS/status/1975520302286450785) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-07T11:15Z 4422 followers, XXX engagements


"#BREAKINGNEWS: Today we announced positive topline results from the TROPION-Breast02 phase X trial for patients with locally recurrent inoperable or metastatic triple negative breast cancer (#TNBC) in collaboration with @AstraZenecaUS. Click the image to learn more. #TNBC"  
[X Link](https://x.com/DaiichiSankyoUS/status/1975158662407840209) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-06T11:18Z 4422 followers, XXX engagements


"#BREAKINGNEWS: The FDA accepted the sBLA for our HER2 directed DXd #ADC followed by a combination regimen for the treatment of adult patients w/ high-risk #HER2 positive early-stage breast cancer prior to surgery in collaboration w/ @AstraZenecaUS. Click to learn more"  
[X Link](https://x.com/DaiichiSankyoUS/status/1973346517252767839) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-01T11:17Z 4422 followers, XXX engagements


"#BREAKINGNEWS: Today we announced the establishment of the Daiichi Sankyo Research Institute in San Diego marking our third research institute outside of our flagship research center in Japan. Click the image to learn more. #ResearchInstitute #PharmaResearch"  
[X Link](https://x.com/DaiichiSankyoUS/status/1973737189914866085) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-02T13:09Z 4422 followers, XXX engagements


"#BREAKINGNEWS: Today during a mini oral session at @MyESMO Daiichi Sankyo announced initial results from one substudy of the TROPION-PanTumor03 phase X trial in patients with locally advanced or metastatic urothelial cancer. Click to learn more. #BladderCancer #ESMO25"  
[X Link](https://x.com/DaiichiSankyoUS/status/1979189488745419041) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-17T14:15Z 4422 followers, XXX engagements


"#NEWS: Throughout @MyESMO we will present more than XX abstracts including two back-to-back presentations during Presidential Symposium I featuring data from the DESTINY-Breast11 & DESTINY-Breast05 phase X trials & late-breaking data from the TROPION-Breast02 phase X trial"  
[X Link](https://x.com/DaiichiSankyoUS/status/1977697830606361036) [@DaiichiSankyoUS](/creator/x/DaiichiSankyoUS) 2025-10-13T11:28Z 4422 followers, XXX engagements